Effect of Cannabidiol in LPS-Induced Toxicity in Astrocytes: Possible Role for Cannabinoid Type-1 Receptors
- 2 October 2023
- journal article
- research article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 41 (6) , 615-626
Abstract
Cerebral metabolic abnormalities are common in neurodegenerative diseases. Previous studies have shown that mitochondrial damage alters ATP production and increases reactive oxygen species (ROS) release which may contribute to neurodegeneration. In the present study, we investigated the neuroprotective effects of cannabidiol (CBD), a non-psychoactive component derived from marijuana (Cannabis sativa L.), on astrocytic bioenergetic balance in a primary cell culture model of lipopolysaccharide (LPS)-induced neurotoxicity. Astrocytic metabolic profiling using an extracellular flux analyzer demonstrated that CBD decreases mitochondrial proton leak, increased spare respiratory capacity and coupling efficiency in LPS-stimulated astrocytes. Simultaneously, CBD increased astrocytic glycolytic capacity and glycolysis reserve in a cannabinoid receptor type 1 (CB1)-dependent manner. CBD-restored metabolic changes were correlated with a significant decrease in the pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) concentration and reduction of ROS production in LPS-stimulated astrocytes. These results suggest that CBD may inhibit LPS-induced metabolic impairments and inflammation by enhancing astrocytic metabolic glycolysis versus oxidative phosphorylation through its action on CB1 receptors. The present findings suggest CBD as a potential anti-inflammatory treatment in metabolic pathologies and highlight a possible role for the cannabinoidergic system in the modulation of mitochondrial oxidative stress. Graphical Abstract CBD enhances mitochondrial bioenergetic profile, attenuates proinflammatory cytokines release, and ROS overproduction of astrocytes stimulated by LPS. These effects are not mediated directly by CB1 receptors, while these receptors seem to have a key role in the anti-inflammatory response of the endocannabinoid system on astrocytes, as their specific inhibition by SR141716A led to increased pro-inflammatory cytokines release and ROS production. The graphical abstract is created with BioRender.com.Keywords
All Related Versions
This publication has 55 references indexed in Scilit:
- Genomic Analysis of Reactive AstrogliosisThe Journal of Neuroscience, 2012
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ InvolvementPLOS ONE, 2011
- Inflammation in the early stages of neurodegenerative pathologyJournal of Neuroimmunology, 2011
- Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88‐dependent NFκB signaling, MAPK, and Jak1/Stat1 pathwaysGlia, 2010
- Cannabinoids Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-κB and Interferon-β/STAT Proinflammatory Pathways in BV-2 Microglial CellsJournal of Biological Chemistry, 2010
- Regulatory Role of TLR Ligands on the Activation of Autoreactive T Cells by Retinal AstrocytesInvestigative Ophthalmology & Visual Science, 2009
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herbTrends in Pharmacological Sciences, 2009
- Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+LevelsThe Journal of Neuroscience, 2009
- Kinetics of inflammatory response of astrocytes induced by TLR 3 and TLR4 ligationJournal of Neuroscience Research, 2006
- Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. IJournal of the American Chemical Society, 1940